HC Wainwright Has Bearish Outlook for SNDX FY2025 Earnings

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) – Analysts at HC Wainwright reduced their FY2025 EPS estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst E. White now expects that the company will post earnings of ($3.86) per share for the year, down from their prior forecast of ($3.76). HC Wainwright has a “Buy” rating and a $51.00 price objective on the stock. The consensus estimate for Syndax Pharmaceuticals’ current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ FY2026 earnings at ($2.97) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The company had revenue of $7.68 million during the quarter, compared to analysts’ expectations of $86.32 million.

A number of other analysts have also recently issued reports on the company. Scotiabank lowered their price objective on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 8th. The Goldman Sachs Group raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Citigroup cut their target price on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating on the stock in a research report on Tuesday. StockNews.com downgraded Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 23rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of Syndax Pharmaceuticals from $35.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Syndax Pharmaceuticals Trading Up 0.7 %

Shares of Syndax Pharmaceuticals stock opened at $14.48 on Thursday. The company’s fifty day simple moving average is $14.29 and its 200-day simple moving average is $16.69. Syndax Pharmaceuticals has a 1 year low of $12.06 and a 1 year high of $25.16. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -3.99 and a beta of 0.90.

Insider Transactions at Syndax Pharmaceuticals

In related news, CFO Keith A. Goldan sold 3,777 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $58,543.50. Following the sale, the chief financial officer now owns 90,746 shares in the company, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $205,964.00. Following the completion of the transaction, the chief executive officer now directly owns 300,121 shares of the company’s stock, valued at $4,651,875.50. This trade represents a 4.24 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 21,683 shares of company stock worth $336,087. 4.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Simplify Asset Management Inc. raised its position in Syndax Pharmaceuticals by 62.5% in the third quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock valued at $2,352,000 after purchasing an additional 46,992 shares during the last quarter. Franklin Resources Inc. raised its holdings in Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after buying an additional 208,043 shares during the last quarter. State Street Corp boosted its position in Syndax Pharmaceuticals by 4.1% during the 3rd quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after buying an additional 148,491 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Syndax Pharmaceuticals by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock worth $13,397,000 after acquiring an additional 41,458 shares during the last quarter. Finally, Barclays PLC increased its position in Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after acquiring an additional 110,535 shares during the period.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).